The trial is for people with patients on current TARPEYO treatment
Study Goal
NefXtend seeks to assess the treatment benefit on kidney function (UPCR, eGFR, 24-hour proteinuria, and microhematuria) as well as evaluate the safety of a 15-month treatment extension of TARPEYO in patients with further treatment needs.
What is involved for the Patient?
Patients consenting to study participation will complete screening assessments prior to stopping their current TARPEYO treatment. Patients qualifying for the study will have 7 study visits over 18 months. Participants’ health is monitored by blood and urine testing, blood pressure and heart rate measurements, and physical exams.
About the drug or intervention
TARPEYO® is recommended as a 9-month treatment. The extended use of TARPEYO in this clinical study is investigational.
